RNXT (RenovoRx) Debt-to-Revenue : N/A (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is RenovoRx Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

RenovoRx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. RenovoRx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. RenovoRx's annualized Revenue for the quarter that ended in Sep. 2024 was $0.00 Mil.

RenovoRx Debt-to-Revenue Historical Data

The historical data trend for RenovoRx's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovoRx Debt-to-Revenue Chart

RenovoRx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

N/A

RenovoRx Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	N/A

Competitive Comparison of RenovoRx's Debt-to-Revenue

For the Biotechnology subindustry, RenovoRx's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RenovoRx's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovoRx's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where RenovoRx's Debt-to-Revenue falls into.

RenovoRx Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

RenovoRx's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	N/A
	=	N/A

RenovoRx's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

RenovoRx Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of RenovoRx's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

RenovoRx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovoRx Inc (NAS:RNXT) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

4546 El Camino Real, Suite B1, Los Altos, CA, USA, 94022

Website

https://www.renovorx.com

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Executives

Angela Nelms	officer: Chief Operating Officer	C/O RENOVORX, INC., 4546 EL CAMINO REAL, SUITE B1, LOS ALTOS CA 94022
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
James M Ahlers	officer: Chief Financial Officer	2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Ramtin Agah	director, officer: Chief Medical Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Shaun Bagai	director, officer: Chief Executive Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Bank Of The West	10 percent owner	PO BOX 60078, LOS ANGELES CA 90060
Una S Ryan	director	329 HAMMOND STREET, CHESTNUT HILL MA 02467
David Diamond	director	29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Laurence Marton	director	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kirsten Angela Macfarlane	director	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Christopher John Lehman	officer: Chief Financial Officer	65 OAK RIDGE ROAD, BERKELEY, BERKELEY CA 94705
Paul Manners	officer: Chief Financial Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kamran Najmabadi	10 percent owner	3114 DAVID AVE., PALO ALTO CA 94303
Najmabadi Family Trust Dated April 22, 2021	10 percent owner	3114 DAVID AVE., PALO ALTO CA 94303